嗜睡症市场 - 全球产业规模、份额、趋势、机会和预测，按类型、按诊断、按治疗、按最终用户、按地区和竞争细分，2020 年至 2030 年

2024 年全球发作性睡病市场价值为 34.3 亿美元，预计到 2030 年将达到 52.4 亿美元，预测期内的复合年增长率为 7.45%。全球发作性睡病市场正在稳步增长，这得益于人们对该疾病认识的不断提高以及诊断技术和治疗方案的进步。发作性睡病是一种慢性神经系统疾病，其特征是白天过度嗜睡和突然肌肉无力（也称为猝倒），近年来得到了更多的重视，导致全球诊断率更高。推动市场成长的主要因素之一是开发创新疗法，以改善症状管理和患者生活品质。例如，美国国家神经疾病和中风研究所估计美国有 135,000 至 200,000 人患有发作性睡病。压力水平的上升导致盛行率上升，因此预计未来几年确诊的发作性睡病患者数量将会增加。同样，根据美国神经病学会的研究，在欧洲国家，该疾病的盛行率为每十万人20至67人不等。中枢神经系统兴奋剂等传统治疗方法已被食慾素受体激动剂和缓释製剂等新型药物所补充，这些药物的疗效和便利性均有所提升。这些进展有助于满足那些常常受现有疗法限制困扰的患者尚未满足的医疗需求。然而，市场仍面临挑战，包括因发作性睡病的症状与其他睡眠障碍或神经系统疾病重迭而导致的漏诊和误诊。诊断延迟可能会妨碍及时治疗，并对患者的预后产生负面影响。

一些先进疗法的高昂成本可能会限制资源匮乏地区患者的治疗，从而限制整体市场覆盖范围。从地理来看，市场在医疗基础设施完善且对睡眠障碍认知度较高的地区最为发达。同时，随着医疗体系的完善和诊断能力的提升，新兴市场预计将迎来更快的成长。研发投入的不断增加也为新型治疗方法铺平了道路，包括旨在更好地监测和管理发作性睡病症状的个人化医疗和数位健康解决方案。随着科技进步不断改善诊断和治疗方案，全球发作性睡病市场前景光明，为改善全球患者预后和提高生活品质带来了希望。

关键市场驱动因素

睡眠障碍盛行率上升

主要市场挑战

漏诊及误诊

主要市场趋势

创新疗法的出现

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：临床试验分析

第六章：全球嗜睡症市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（类型 1、类型 2、其他）
  • 按诊断（多导睡眠图、多次睡眠潜伏期测试、其他）
  • 依治疗方法（兴奋剂、抗忧郁剂、羟基丁酸钠等）
  • 按最终用户（医院、诊所、零售药局、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第七章：北美嗜睡症市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第八章：欧洲嗜睡症市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第九章：亚太地区嗜睡症市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第十章：南美洲嗜睡症市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲嗜睡症市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：市场动态

• 驱动程式
• 嗜睡症盛行率上升
• 政府机关的措施日益增多
• 挑战
• 与嗜睡症药物相关的不良反应。
• 与发作性睡病治疗相关的误诊

第十三章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 14 章：全球嗜睡症市场：SWOT 分析

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章：竞争格局

• Jazz Pharmaceuticals Plc.
• BIOPROJET.
• Arena Pharmaceuticals, Inc.
• Graymark Healthcare, Inc.
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Novartis AG.
• Shire.
• Shionogi Inc.
• Ligand Pharmaceuticals, Inc.

第 17 章：策略建议

第18章调查会社について・免责事项

Global Narcolepsy Market was valued at USD 3.43 billion in 2024 and is expected to reach USD 5.24 billion by 2030 with a CAGR of 7.45% during the forecast period. The global narcolepsy market is experiencing steady growth, driven by increasing awareness of the disorder and advancements in diagnostic techniques and treatment options. Narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness and sudden muscle weakness known as cataplexy, has gained more recognition in recent years, leading to higher diagnosis rates worldwide. One of the primary factors fueling market growth is the development of innovative therapies that improve symptom management and patient quality of life. For instance, the National Institute of Neurological Disorders and Stroke estimates 135,000 to 200,000 people in the U.S. have narcolepsy. Rising stress levels contribute to increasing prevalence, so the number of diagnosed narcolepsy patients is expected to grow in the coming years. Similarly, according to the study conducted by the American Academy of Neurology, the prevalence of the disease varies from 20 to 67 per 100,000 individuals in European countries. Traditional treatments such as central nervous system stimulants have been supplemented by newer medications, including orexin receptor agonists and extended-release formulations, which offer enhanced efficacy and convenience. These advancements have helped address the unmet medical needs of patients who often struggle with the limitations of existing therapies. However, the market still faces challenges, including the underdiagnosis and misdiagnosis of narcolepsy due to symptom overlap with other sleep disorders or neurological conditions. This delay in diagnosis can hinder timely treatment and negatively impact patient outcomes.

The high cost of some advanced therapies may restrict access for patients in low-resource settings, limiting the overall market reach. Geographically, the market is most developed in regions with well-established healthcare infrastructure and greater awareness of sleep disorders. Meanwhile, emerging markets are expected to witness faster growth as healthcare systems improve and diagnostic capabilities expand. Increasing investment in research and development is also paving the way for novel therapeutic approaches, including personalized medicine and digital health solutions aimed at better monitoring and managing narcolepsy symptoms. The global narcolepsy market holds promising potential as advancements continue to improve diagnosis and treatment options, offering hope for better patient outcomes and enhanced quality of life worldwide.

Key Market Drivers

Rising Prevalence of Sleep Disorders

The rising prevalence of sleep disorders is a significant factor influencing the growth of the global narcolepsy market. Sleep disorders encompass a wide range of conditions that disrupt normal sleep patterns, including insomnia, sleep apnea, restless leg syndrome, and narcolepsy. Among these, narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, sudden muscle weakness (cataplexy), and disrupted nighttime sleep. As awareness of sleep health improves and diagnostic techniques become more sophisticated, more individuals are being identified with these conditions, contributing to a growing patient population seeking medical intervention.Several lifestyle and environmental factors have contributed to the increasing occurrence of sleep disorders worldwide. Modern lifestyles marked by high stress levels, irregular sleep schedules, increased screen time, and urbanization have negatively impacted sleep quality for many people. Additionally, the global rise in comorbid conditions such as obesity, mental health disorders, and cardiovascular diseases-which are closely linked to sleep disturbances-has further fueled the prevalence of sleep-related issues. This broader trend creates a conducive environment for the narcolepsy market as individuals experiencing symptoms are more likely to seek specialized treatment.

From a market perspective, the rising prevalence translates into heightened demand for effective diagnostic tools and therapeutic solutions. Improved screening methods allow for earlier and more accurate diagnosis, enabling timely intervention. As more patients are diagnosed with narcolepsy, pharmaceutical companies and healthcare providers are motivated to develop and offer advanced treatment options tailored to patient needs. This includes innovative drugs that target underlying causes or provide better symptom control, as well as supportive therapies that enhance quality of life. The growing patient pool encourages investment in research and development, further advancing the narcolepsy treatment landscape. Healthcare systems worldwide are also recognizing the economic and social burdens of untreated sleep disorders, prompting initiatives to improve access to care. Overall, the rising prevalence of sleep disorders acts as a crucial driver for the narcolepsy market, fostering growth and innovation aimed at meeting increasing patient demand.

Key Market Challenges

Underdiagnosis and Misdiagnosis

Underdiagnosis and misdiagnosis remain significant challenges impacting the growth and effectiveness of the global narcolepsy market. Narcolepsy is a complex neurological disorder characterized by symptoms such as excessive daytime sleepiness, cataplexy (sudden muscle weakness), and disrupted nighttime sleep. However, these symptoms often overlap with those of other more common conditions, including insomnia, depression, epilepsy, and general fatigue. This similarity frequently leads to confusion among healthcare providers, resulting in delayed or incorrect diagnoses. The underdiagnosis of narcolepsy is widespread, with many patients remaining undiagnosed for years after symptom onset. This delay can have serious consequences on patient quality of life, as untreated symptoms impair daily functioning, cognitive performance, and emotional wellbeing. Moreover, underdiagnosis limits the number of patients receiving appropriate treatment, directly affecting the market size and growth potential for narcolepsy therapies.

Misdiagnosis also poses a critical problem, as patients may be treated for conditions they do not have, leading to ineffective therapy and further deterioration of their condition. The absence of specialized sleep disorder clinics and limited access to advanced diagnostic tools in many regions exacerbate this issue. Additionally, a lack of awareness and training among general practitioners and even some specialists contributes to diagnostic challenges. From a market perspective, overcoming underdiagnosis and misdiagnosis is essential for unlocking the full potential of narcolepsy treatment demand. Improving awareness campaigns, enhancing education for healthcare professionals, and expanding access to reliable diagnostic methods such as polysomnography and multiple sleep latency tests are critical steps. As diagnosis rates improve, more patients will seek treatment, driving innovation and growth in the narcolepsy therapeutics market.

Key Market Trends

Emergence of Innovative Therapies

The emergence of innovative therapies is transforming the global narcolepsy market by offering more effective and patient-friendly treatment options. Traditional narcolepsy treatments primarily focused on managing symptoms like excessive daytime sleepiness and cataplexy through stimulants and sodium oxybate. However, these treatments often had limitations related to side effects, dosing frequency, and variable efficacy, which impacted patient adherence and quality of life. Recent advancements in pharmacology have introduced novel therapies targeting the underlying mechanisms of narcolepsy, particularly the orexin (hypocretin) system, which plays a crucial role in regulating wakefulness. Orexin receptor agonists represent a new class of drugs designed to directly address the root cause of narcolepsy rather than just alleviating symptoms. These innovative agents have demonstrated promising results in clinical trials, showing improved efficacy with fewer side effects compared to conventional medications.

The pharmaceutical companies are developing extended-release formulations of existing drugs, such as once-nightly sodium oxybate, which improve convenience and encourage better adherence by reducing the need for multiple daily doses. This approach enhances patient compliance and overall treatment outcomes. The market is also witnessing the introduction of therapies approved for pediatric use, expanding treatment availability to younger patients who were previously underserved. This broadens the patient base and underscores the importance of inclusive treatment development. The rise of innovative therapies in the narcolepsy market is driving growth by meeting unmet clinical needs and improving patient quality of life. These advancements are encouraging ongoing research and investment, fostering a competitive landscape focused on delivering safer, more effective, and tailored treatment options for narcolepsy patients worldwide.

Key Market Players

• Jazz Pharmaceuticals Plc.
  • BIOPROJET.
  • Arena Pharmaceuticals, Inc.
  • Graymark Healthcare, Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
  • Novartis AG.
• Shire.
• Shionogi Inc.
• Ligand Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Narcolepsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Narcolepsy Market, By Type:

• Type 1
• Type 2
• Others

Narcolepsy Market, By Diagnosis:

• Polysomnogram
• Multiple Sleep Latency Test
• Others

Narcolepsy Market, By Treatment:

• Stimulants
• Antidepressants
• Sodium Oxybate
• Others

Narcolepsy Market, By End User:

• Hospitals
• Clinics
• Retail Pharmacies
• Others

Narcolepsy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Market.

Available Customizations:

Global Narcolepsy Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Narcolepsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Type 1, Type 2, Others)
  • 6.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 6.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 6.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map

7. North America Narcolepsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Type 1, Type 2, Others)
  • 7.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 7.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 7.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Narcolepsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By Treatment
      • 7.3.1.2.4. By End User
  • 7.3.2. Canada Narcolepsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By Treatment
      • 7.3.2.2.4. By End User
  • 7.3.3. Mexico Narcolepsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By Treatment
      • 7.3.3.2.4. By End User

8. Europe Narcolepsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Type 1, Type 2, Others)
  • 8.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 8.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 8.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Narcolepsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By Treatment
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Narcolepsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By Treatment
      • 8.3.2.2.4. By End User
  • 8.3.3. United Kingdom Narcolepsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By Treatment
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Narcolepsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By Treatment
      • 8.3.4.2.4. By End User
  • 8.3.5. Spain Narcolepsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By Treatment
      • 8.3.5.2.4. By End User

9. Asia-Pacific Narcolepsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Type 1, Type 2, Others)
  • 9.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 9.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 9.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Narcolepsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By Treatment
      • 9.3.1.2.4. By End User
  • 9.3.2. India Narcolepsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By Treatment
      • 9.3.2.2.4. By End User
  • 9.3.3. Japan Narcolepsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By Treatment
      • 9.3.3.2.4. By End User
  • 9.3.4. South Korea Narcolepsy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Diagnosis
      • 9.3.4.2.3. By Treatment
      • 9.3.4.2.4. By End User
  • 9.3.5. Australia Narcolepsy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Type
      • 9.3.5.2.2. By Diagnosis
      • 9.3.5.2.3. By Treatment
      • 9.3.5.2.4. By End User

10. South America Narcolepsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Type 1, Type 2, Others)
  • 10.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 10.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 10.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Narcolepsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By Treatment
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Narcolepsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By Treatment
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Narcolepsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By Treatment
      • 10.3.3.2.4. By End User

11. Middle East and Africa Narcolepsy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Type (Type 1, Type 2, Others)
  • 11.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 11.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 11.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Narcolepsy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Type
      • 11.3.1.2.2. By Diagnosis
      • 11.3.1.2.3. By Treatment
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Narcolepsy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Type
      • 11.3.2.2.2. By Diagnosis
      • 11.3.2.2.3. By Treatment
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Narcolepsy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Type
      • 11.3.3.2.2. By Diagnosis
      • 11.3.3.2.3. By Treatment
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.1.1 Increase in Prevalence of Narcolepsy
• 12.1.2 Growing Initiatives by Government Organizations
• 12.2. Challenges
• 12.2.1 Adverse effect related to narcolepsy drugs.
• 12.2.2 Misdiagnosis related to narcolepsy treatment

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Narcolepsy Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1 Jazz Pharmaceuticals Plc.
• 16.2 BIOPROJET.
• 16.3 Arena Pharmaceuticals, Inc.
• 16.4 Graymark Healthcare, Inc.
• 16.5 Mylan N.V.
• 16.6 Teva Pharmaceutical Industries Ltd.
• 16.7 Novartis AG.
• 16.8 Shire.
• 16.9 Shionogi Inc.
• 16.10 Ligand Pharmaceuticals, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer